Pharma has challenges…Nuritas has solutions!

A new paradigm in drug discovery…

  • Despite billions invested in the discovery of new drugs, most efforts end in failure; the failure rate has changed little in the last decade
  • Peptides are the major path of biological signaling in plants and animals, and provide a largely untapped landscape of opportunity for drug discovery
  • By applying artificial intelligence to the discovery process, Nuritas can increase the chance of success in early stage drug discovery
  • Our AI platform allows us to create customized discovery templates that can predict the candidates from the vast universe of peptides in our library that are most likely to meet the key criteria for commercial development
Contact us

Case Study: The Nuritas AI-powered NπΦ platform has discovered a novel peptide that demonstrates activity against a multi-modal fibrosis target

The Pannexin 1 Pathway
Increased inflammatory signaling in the Pannexin 1 (Panx1) ion channel stimulates release of pro-inflammatory cytokines, TGF-beta, TNF-alpha, and PDGF, driving fibrotic pathology, thus providing a discovery platform for a range of fibrotic diseases

Liver disease
Panx1 is a validated target in liver fibrogenesis.(1)

Renal disease
Pharmacological inhibition of Panx1 and genetic deletion of Panx1 globally, in proximal tubule or in vascular endothelium in mouse, are protective against ischemic AKI. (2)

Cardiac disease
Cardiomyocytes have been shown to release ATP via Panx1 which contributes to activation of fibroblasts (Dolmatova et al., 2012).(3)

(1) Arch Toxicol. 2018 August ; 92(8): 2607–2627. doi:10.1007/s00204-018-2255-3
(2) J Am Soc Nephrol. 2018 Jul;29(7):1887-1899. doi: 10.1681/ASN.2017121306. Epub 2018 Jun 4.
(3) Am J Physiol Heart Circ Physiol. 2012;303:H1208–H1218

Request brochure

Nuritas – Inspired by Nature, Delivered by Technology

Discovery is the art of looking beyond the obvious

Nuritas Scientific Advisory Board

Bioavailability collaboration with Prof David Braydon